{"url_path":"/sec/zntl/8-k/2026-05-21/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1725160/0001725160-26-000045-index.html","accession_number":"0001725160-26-000045","cik":"0001725160","ticker":"ZNTL","issuer_name":"Zentalis Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1725160/0001725160-26-000045-index.html","primary_entity_key":"0001725160","primary_entity_name":"Zentalis Pharmaceuticals, Inc."},"word_count":127,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn May 21, 2026, Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) issued the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”) and incorporated herein by reference.\n\nThe information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing."}